Literature DB >> 2744084

Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model.

W Löscher1, R Jäckel, F Müller.   

Abstract

The effects of three drugs, namely gamma-vinyl GABA (vigabatrin), gamma-acetylenic GABA, and aminooxyacetic acid, which increase brain GABA concentrations by irreversible inhibition of GABA degradation, were studied in amygdala-kindled rats. Vigabatrin 800 or 1,200 mg/kg i.p. 4 h after its administration, caused prolongation of behavioural seizures and electrographic afterdischarges recorded from the stimulated amygdala. One to three days after administration it dose dependently reduced seizure severity, seizure duration and afterdischarge duration in most animals. Determination of GABA levels in synaptosomes isolated from 12 brain regions of kindled rats 4 or 48 h after injection of 1,200 mg/kg vigabatrin indicated that the variable effects of this drug at different times after its administration could be related to differences in the time course of nerve terminal GABA increases in selective brain regions such as amygdala and corpus striatum. In contrast to vigabatrin, gamma-acetylenic GABA, 100 mg/kg i.p., reduced seizure severity in kindled rats as early as 4 h after its administration but afterdischarge duration increased significantly on subsequent days. Similar late increases in afterdischarge duration (and limbic seizure activity) after the time of maximum anticonvulsant effect had elapsed were also observed with vigabatrin, which could suggest that the anticonvulsant effect of such drugs is followed by withdrawal hyperexcitability. Aminooxyacetic acid, 20 mg/kg i.p., exerted no significant anticonvulsant effect in kindled rats but prolonged afterdischarge duration in several of the animals studied. The data suggest that GABA-T inhibitors, such as vigabatrin, differ from most antiepileptic drugs previously tested in the kindling model in that they may produce both anticonvulsant and proconvulsant effects at the same dose in the same animal as a function of time after administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744084     DOI: 10.1016/0014-2999(89)90389-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.

Authors:  D Hönack; C Rundfeldt; W Löscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

Review 2.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

3.  Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs.

Authors:  U Eckstein-Ludwig; J Fei; W Schwarz
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 4.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

5.  Plasticity of rat central inhibitory synapses through GABA metabolism.

Authors:  D Engel; I Pahner; K Schulze; C Frahm; H Jarry; G Ahnert-Hilger; A Draguhn
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

6.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

7.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

8.  Biphasic action of vigabatrin on cortical epileptic after-discharges in rats.

Authors:  Pavel Mares; Romana Slamberová
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-07       Impact factor: 3.000

Review 9.  The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids.

Authors:  Bruno Gasnier
Journal:  Pflugers Arch       Date:  2003-05-16       Impact factor: 3.657

Review 10.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.